Is Bliss GVS Pharma overvalued or undervalued?

As of 14 July 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 19.15, an EV to EBITDA ratio of 11.75, and a Price to Book Value of 1.54. In comparison to its peers, Bliss GVS Pharma's valuation metrics stand out favorably; for instance, Sun Pharma has a significantly higher PE ratio of 35.28, while Cipla, another peer, has a PE ratio of 22.74, reinforcing Bliss GVS Pharma's attractive positioning.
Despite a recent decline in stock price, with a year-to-date return of -7.01% compared to the Sensex's 5.27%, the company's fundamentals suggest it is well-positioned for growth. With a PEG ratio of 0.00 and a ROCE of 10.51%, Bliss GVS Pharma demonstrates strong potential for future earnings relative to its current price, further supporting the conclusion that it is undervalued in the current market.